| Active ingredient: selpercatinib |
| Brand name (sponsor): Retevmo (Eli Lilly) |
| Presentation: 40 mg and 80 mg immediate-release hard capsules |
| Route of administration: oral |
| Approved indication: provisionally approved for the treatment of adult patients with locally advanced or metastatic RET (rearranged during transfection) fusion-positive non-small cell lung cancer |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.